A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
There is an urgent need for new treatments for chronic kidney disease (CKD). Thymosin-b4 is a peptide that reduces inflammation and fibrosis and has the potential to restore endothelial and epithelial cell injury, biological processes involved in the pathophysiology of CKD. Therefore, thymosin-b4 could be a novel therapeutic direction for CKD. Areas covered: Here, we review the current evidence on the actions of thymosin-b4 in the kidney in health and disease. Using transgenic mice, two recentdoi:10.1080/14712598.2018.1473371 pmid:29727205 fatcat:jps4l3qjxfbkxj22mbe64ta5cm